Search research articles
Contact Us
Filters
Showing results (381-390 of 426) with videos related to
Page
of 43
Sort By:
Cancer Discovery
|
April 21, 2021
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease
Amy C Mandigo, Wei Yuan, Kexin Xu, et al.
The Lancet. Oncology
|
January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J Ryan, Matthew R Smith, Karim Fizazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
B Basu, M G Krebs, R Sundar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study
Joo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
International Journal of Cancer
|
July 15, 2018
Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap)
Kiki C Andree, Anouk Mentink, Leonie L Zeune, et al.
The New England Journal of Medicine
|
June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapy
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
European Urology Oncology
|
July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer
Sandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2018
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Gunther Boysen, Daniel N Rodrigues, Pasquale Rescigno, et al.
The Journal of Clinical Investigation
|
December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo, George Seed, Claudia Bertan, et al.
Page
of 43
Search research articles
Search
Showing results (381-390 of 426) with videos related to
Sort By:
Page
of 43
Cancer Discovery
|
April 21, 2021
RB/E2F1 as a Master Regulator of Cancer Cell Metabolism in Advanced Disease
Amy C Mandigo, Wei Yuan, Kexin Xu, et al.
The Lancet. Oncology
|
January 21, 2015
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Charles J Ryan, Matthew R Smith, Karim Fizazi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 18, 2018
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
B Basu, M G Krebs, R Sundar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 5, 2022
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors
Atish D Choudhury, Celestia S Higano, Johann S de Bono, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2013
Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study
Joo Ern Ang, Charlie Gourley, C Bethan Powell, et al.
International Journal of Cancer
|
July 15, 2018
Toward a real liquid biopsy in metastatic breast and prostate cancer: Diagnostic LeukApheresis increases CTC yields in a European prospective multicenter study (CTCTrap)
Kiki C Andree, Anouk Mentink, Leonie L Zeune, et al.
The New England Journal of Medicine
|
June 3, 2014
Enzalutamide in metastatic prostate cancer before chemotherapy
Tomasz M Beer, Andrew J Armstrong, Dana E Rathkopf, et al.
European Urology Oncology
|
July 12, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer
Sandra van Wilpe, Tarek Taha, Emily C Rothmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2018
SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Gunther Boysen, Daniel N Rodrigues, Pasquale Rescigno, et al.
The Journal of Clinical Investigation
|
December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistance
Joaquin Mateo, George Seed, Claudia Bertan, et al.
Page
of 43